Clinical Trial Update: Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial [Phase 2, Phase 3]

View source ↗

Summary

A prospective randomized controlled trial is investigating myo-inositol for managing poor ovarian responders in a Phase 2/Phase 3 setting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poor Ovarian Response

Drugs mentioned

• Myo-inositol (myo-inositol)

Snippet

Sponsor: American University of Beirut Medical Center | Conditions: Poor Ovarian Response | Phase 2, Phase 3 | Status: UNKNOWN